"Stilla’s next-generation digital PCR solutions would make a compelling and complementary addition to Bio-Rad’s best-in-class digital PCR portfolio,” said Norman Schwartz, CEO of Bio-Rad ...

The SARS-CoV-2 Droplet Digital PCR (ddPCR) test runs on Bio-Rad's QX200 and QXDx ddPCR systems. The high sensitivity of the test makes it well suited to screening upper respiratory samples in patients ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay ...

Bio-Rad Laboratories, Inc.’s BIO solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees ...

This research collaboration aims to generate clinical evidence across a range of cancer types to support the implementation of Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology for tumor-informed ...

Technical advances and enhanced automation are taking droplet digital PCR from a specialized ... and integration effort is California-based Bio-Rad’s recently commercialized QX ONE platform ...

Bio-Rad Laboratories, Inc. BIO recently entered into a binding agreement to purchase all equity interests in Stilla Technologies ("Stilla"). Stilla’s next-generation digital PCR solutions ...

A major advantage of drop-off digital PCR is the single-assay detection of multiple proximal genetic lesions (including deletions, insertions and nucleotide substitutions) within a short genomic ...

Ultra-rapid digital droplet PCR can measure the levels of tumor cells in a tissue sample during surgery in about 15 minutes.